Abstract: PO1931
Lupus Podocytopathy Systematic Review
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Trials - 3
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Claudio-Gonzalez, Ivan L., Emory University Woodruff Health Sciences Center, Atlanta, Georgia, United States
- Rajabalan, Ajai S., Emory University Woodruff Health Sciences Center, Atlanta, Georgia, United States
- Navarrete, Jose E., Emory University Woodruff Health Sciences Center, Atlanta, Georgia, United States
- Cobb, Jason, Emory University Woodruff Health Sciences Center, Atlanta, Georgia, United States
Background
Patients with lupus, can present with a renal lesion distinct from the ones described by the ISN/RPS classification of lupus nephritis called lupus podocytopathy. Lupus podocytopathy has been described as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) in patients with SLE with or without mesangial involvement but without proliferative or membranous lupus nephritis features. We have gathered the available data on lupus podocytopathy and analyzed it to provide a comprehensive report in this review.
Methods
We searched electronic databases including pubmed and google scholar , using keywords related to lupus podocytopathy and synonyms and treatment from inception to December 2019. Articles retrieved were screened for relevance, including reference list of retrieved. We included cohort studies, case series, and retrospective studies. Individual case reports were excluded.
Results
The search identified 8 studies, of which 6 were included with a total of 107 patients. The patients were predominantly female (88%). The average age was 35 years. Studies done outside of China had predominantly African-American patients 72.5%. The average serum creatinine was 2.06 mg/dL. The average proteinuria was 6.5 g/day. Four studies reported monotherapy corticosteroids, and three studies reported varied treatments. The average follow up was 3.7 years. Complete remission was reported to be 67% from 3 studies. Four studies reported relapse rate of patients, and it accounted to 72.5% of patients.
Conclusion
Our study is the first systematic review of lupus podocytopathy. The strength of this study is the merger of data from known studies in lupus podocytopathy which is a rare but important disease entity in lupus patients with renal disease. The treatment and possible prognosis of lupus podocytopathy patients are different from proliferative and membranous lupus nephritis, and physicians should be aware of this process. Patients can be spared from unwarranted immunosuppressive medications and their side effects. Greater collaborations and biopsies are needed to learn more about this interesting disease process.